Before joining DHC, John served as CTO of Tessa Therapeutics. Tessa Therapeutics is a clinical-stage biotechnology company based in Singapore that is developing a portfolio of autologous and allogeneic cell therapy assets.
John joined Tessa Therapeutics as a member of its executive leadership team in 2016 and grew the company from 30 people to more than 200 people. In 2021, he was asked by the Board of Directors to become the Acting CEO, where he led the company to complete a USD $126M fundraising round.
He led the design, build, and validation of their multi-product integrated commercial cGMPfacility (134,000 sq ft). The facility obtained the GMP certificate from the Health Authority of Singapore (HSA) to manufacture cell therapy products in early 2023.
As the CTO, John was responsible for the Operations organization, which includes Manufacturing, Process Development, Quality, Program Management, Engineering, and Global Supply Chain. Under his leadership, Tessa Therapeutics completed a phase 3 pivotal autologous cell therapy trial supplied by in-house manufacturing. He also led the translation of multiple programs with Tessa’s academic partners, executing successful tech transfers and comparability runs.
Before Tessa Therapeutics, John served in various leadership roles in Technical Operations in publicly listed companies. He spent ten years in China, responsible for Procurement, Global Supply Chain, and Program management.